Asked by: Alison Hume (Labour - Scarborough and Whitby)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure the adequacy of patient access to (a) Creon and (b) other pancreatic enzyme replacement medications; and whether he has had recent discussions with (i) NHS England and (ii) pharmaceutical companies on supplies of such medication.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department has been working with suppliers to address current supply issues with Creon, which is used by patients with conditions such as cystic fibrosis and certain cancers including pancreatic cancer. The supply issues with Creon are impacting countries throughout Europe and have been caused by limited availability of raw ingredients and manufacturing capacity constraints to produce volumes needed to meet demand. These issues have resulted in knock-on supply disruptions of alternative pancreatic enzyme replacement therapy medications. The Department is continuing to work with all suppliers of pancreatic enzyme replacement therapy to help resolve the supply issues in the short and longer term. This includes asking that they expedite deliveries, source stock from other markets, and increase production.
The supplier of Creon has advised that they expect to have regular supplies released each month going forward and are working to increase the quantities released. Serious Shortage Protocols are in place for Creon 10,000 and 25,000 capsules which pharmacists can use to restrict supply to one month at a time to ensure more patients have access to it whilst stock is limited.
We have worked closely with colleagues in NHS England to issue comprehensive guidance to healthcare professionals about these supply issues and encourage sharing of local solutions. The guidance provides advice on how to manage patients whilst there is disruption to supply and is being kept under review, with updates made as necessary.
Sep. 05 2024
Source Page: Belzutifan for treating tumours associated with von Hippel-Lindau diseaseFound: care; TTS, time to surgery; VHL, Von Hippel -Lindau 8888Consultation Responses 1/3 Action Kidney Cancer
Found: - Cancer research and data - Cancer patient experience MSP Members of the Group Please provide
Asked by: Mark Pritchard (Conservative - The Wrekin)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure adequate supplies of pancreatic enzyme replacement therapy medication.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department has been working with suppliers to address current supply issues with pancreatic enzyme replacement therapy (PERT), including Creon, used in the treatment of cystic fibrosis and certain cancers, including pancreatic cancer. The supply issues are impacting countries throughout Europe, and have been caused by the limited availability of raw ingredients and manufacturing capacity constraints in producing the volumes needed to meet demand. The Department is continuing to work with all suppliers of PERT to help resolve the supply issues in the short and longer term. This includes asking that they expedite deliveries, source stock from other markets, and increase production.
We have issued comprehensive guidance to healthcare professionals about these supply issues, which provides advice on how to manage patients whilst there is disruption to supply. This guidance is being kept under review, and updates will be made as necessary. Serious Shortage Protocols are in place for Creon 10,000 and 25,000 capsules to limit prescriptions to one months’ supply, to allow demand management.
We understand how frustrating and distressing medicine supply issues can be. While we can’t always prevent supply issues from occurring, the Department has a range of well-established processes and tools to manage them when they arise, and to help mitigate risks to patients.
Asked by: John Hayes (Conservative - South Holland and The Deepings)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will take steps to ensure the supply of pancreatic enzyme replacement therapies for people with cystic fibrosis.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department has been working with suppliers to address current supply issues with pancreatic enzyme replacement therapy (PERT), including Creon, used in the treatment of cystic fibrosis and certain cancers, including pancreatic cancer. The supply issues are impacting countries throughout Europe, and have been caused by the limited availability of raw ingredients and manufacturing capacity constraints in producing the volumes needed to meet demand. The Department is continuing to work with all suppliers of PERT to help resolve the supply issues in the short and longer term. This includes asking that they expedite deliveries, source stock from other markets, and increase production.
We have issued comprehensive guidance to healthcare professionals about these supply issues, which provides advice on how to manage patients whilst there is disruption to supply. This guidance is being kept under review, and updates will be made as necessary. Serious Shortage Protocols are in place for Creon 10,000 and 25,000 capsules to limit prescriptions to one months’ supply, to allow demand management.
We understand how frustrating and distressing medicine supply issues can be. While we can’t always prevent supply issues from occurring, the Department has a range of well-established processes and tools to manage them when they arise, and to help mitigate risks to patients.
Asked by: James Naish (Labour - Rushcliffe)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to address regional disparities in cancer treatment.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Reducing inequalities and variation in cancer treatment is a priority for the Government, as is increasing early cancer diagnosis, as both are key contributors to reducing cancer health inequalities.
To improve diagnosis and outcomes, NHS England is delivering a range of interventions including implementing non-specific symptom pathways for patients who have symptoms, such as unexplained weight-loss and fatigue, that do not align to a single tumour type, as is often the case with pancreatic cancer. 115 pathways are now in place across the country, providing almost full population coverage.
We are also rolling out the Targeted Lung Health Checks Programme, which aims to improve early detection of lunch cancer. People living in deprived areas are four times more likely to smoke, and smoking causes 72% of lung cancers. Therefore, introducing this programme will disproportionately benefit those in deprived areas.
Asked by: Andrew Mitchell (Conservative - Sutton Coldfield)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to tackle the shortage of the drug CREON.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department has been working with suppliers to address current supply issues with Creon, which is used by patients with conditions such as cystic fibrosis and certain cancers including pancreatic cancer. The supply issues with Creon are impacting countries throughout Europe and have been caused by limited availability of raw ingredients and manufacturing capacity constraints to produce volumes needed to meet demand. These issues have resulted in knock-on supply disruptions of alternative pancreatic enzyme replacement therapy medications. The Department is continuing to work with all suppliers of pancreatic enzyme replacement therapy to help resolve the supply issues in the short and longer term. This includes asking that they expedite deliveries, source stock from other markets, and increase production.
The supplier of Creon has advised that they expect to have regular supplies released each month going forward and are working to increase the quantities released. Serious Shortage Protocols are in place for Creon 10,000 and 25,000 capsules which pharmacists can use to restrict supply to one month at a time to ensure more patients have access to it whilst stock is limited.
We have worked closely with colleagues in NHS England to issue comprehensive guidance to healthcare professionals about these supply issues and encourage sharing of local solutions. The guidance provides advice on how to manage patients whilst there is disruption to supply and is being kept under review, with updates made as necessary.
Asked by: Lord McColl of Dulwich (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what is the total cost of treating patients who are obese and overweight; and what are the associated costs of treating (1) type 2 diabetes, (2) cardiovascular disease, (3) cerebrovascular disease, (4) musculoskeletal diseases including joint replacers, (5) cancer, and (6) dementia.
Answered by Lord Markham - Shadow Minister (Science, Innovation and Technology)
The department has reviewed and uses cost estimates published by Frontier Economics in 2022.
A study by Frontier Economics estimated that in 2021 obesity related ill-health cost the National Health Service £6.5 billion annually. This estimate includes costs associated with the following obesity related diseases: colorectal cancer; oesophageal cancer; kidney cancer; ovarian cancer; pancreatic cancer; coronary heart disease; stroke; type 2 diabetes; hypertension; knee osteoarthritis; endometrial cancer, and breast cancer.
The disease costs associated with obesity are calculated from the total annual costs per case, as shown in the following table:
Disease | Cost per case per year (2021) |
(1) Type 2 diabetes | £ 827.33 |
(2) Cardiovascular disease - Coronary heart disease (CHD) | £ 1,557.25 |
(2) Cardiovascular disease - Stroke | £ 247.55 |
(2) Risk of Cardiovascular disease - Hypertension | £ 453.91 |
(4) Musculoskeletal disease - Knee Osteoarthritis | £ 27,798.40 |
(5) Cancer - Colorectal cancer | £ 520.13 |
(5) Cancer - Oesophageal cancer | £ 545.06 |
(5) Cancer - Kidney cancer | £ 1,662.88 |
(5) Cancer - Ovarian cancer | £ 14,990.93 |
(5) Cancer - Pancreatic cancer | £ 7,447.27 |
(5) Cancer - Endometrial cancer | £ 520.13 |
(5) Cancer - Breast cancer | £ 545.06 |
The annual costs per case includes direct health-care costs including hospital care (both inpatient and outpatient), primary care, and medication, and they are not exclusively related to obesity associated cases. Indirect and social care costs are not included, which means the exclusion of these costs will probably underestimate total costs of disease events overall.
Mar. 25 2024
Source Page: Implementing a timed HPB cancer diagnostic pathwayFound: Implementing a timed HPB cancer diagnostic pathway
Asked by: Edward Morello (Liberal Democrat - West Dorset)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve support for people living with secondary breast cancer in rural areas.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Reducing unwarranted variation in cancer treatment is a strategic priority for NHS England’s Cancer Programme. The programme was commissioned by the Royal College of Surgeons and aims to deliver 10 cancer clinical audits, including two audits on primary and metastatic breast cancer.
To help improve outcomes and treatments for patients in all areas, NHS England funded an audit into primary and metastatic breast cancer. Using routine data collected on patients diagnosed with pancreatic cancer in a National Health Service setting as part of their care and treatment, the audit brings together information to look at what is being done well, where it’s being done well, and what needs to be done better. On 12 September 2024 the National Cancer Audit Collaborating Centre published their State of the Nation Report on primary and metastatic breast cancer.
The Department supports statutory integrated care systems (ICSs) in delivering NHS services across England. ICSs are partnerships of organisations which come together to plan and deliver joined up health and care services, to improve the lives of the people who live and work in their area. This includes considering adequate healthcare provision for populations in towns and rural areas, and working collaboratively to plan for population change.
The organisations within an ICS include the NHS, local government, social care providers, charities, and other organisations working together to provide more joined up care for people, and to improve the outcomes for their populations.